Phase I study of the novel, oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK): Evaluating the pharmacokinetic effect of a high-fat meal in patients with hormone-refractory prostate cancer (HRPC).
暂无分享,去创建一个
P. Kantoff | W. Oh | D. Lebwohl | D. George | T. Gilligan | E. Masson | Y. Wang | D. Laurent | C. Souppart | Y. Ho